Theoharis C. Theoharides, MS, MPhil, PhD, MD, professor, Nova Southeastern University, Fort Lauderdale, Florida, interviews Lisa Kilt and Julia M. Stewart, RN, who detail their symptoms that have gone undiagnosed thus far. Lisa and Julia discuss their experiences and difficulties. Dr Theoharides describes mast cell science, mast cell activation syndrome, and options for symptom management.
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
